Pharmaceuticals Financial News

The Supreme Court on Monday rejected an appeal from Martin Shkreli, who was once dubbed “Pharma Bro” after jacking up the price of a lifesaving drug

Granules India Ltd.(up 2.72 per cent), Aurobindo Pharma Ltd.(up 1.17 per cent), Divi's Laboratories Ltd.(up 0.67 per cent), Sanofi India Ltd.(up 0.54 per cent) and Dr. Reddy's Laboratories Ltd.(up 0.51 per cent) were among the top gainers.

Subscribe to enjoy similar stories. India last month extended countervailing duties of 12-30% on certain steel imports from China and Vietnam, following requests from local producers to safeguard against cheaper imports. While this stance against Chinese goods is notable, data indicates that overall imports from China are still on the rise, while exports to the country are faltering.

Piyush Goyal discussed the potential investment opportunities in India’s electronics manufacturing, data infrastructure and logistics sectors and new areas of collaboration particularly in advanced manufacturing, pharmaceuticals, robotics, artificial intelligence, and sustainable technologies with American companies during his ongoing visit to the US, commerce and industry ministry said in a statement Tuesday. “He invited American companies to leverage India’s unmatched scale and take advantage of the Make in India initiative, particularly in high-tech manufacturing and quality production,” the ministry said. During his meeting with Blackstone, Goyal said that the company has already invested about $50 billion in India and is one of the largest commercial and real estate investors in the country.

Shares of Granules India Ltd.(up 3.68 per cent), Mankind Pharma Ltd.(up 2.32 per cent), Biocon Ltd.(up 2.08 per cent), Alkem Laboratories Ltd.(up 1.63 per cent) and Laurus Labs Ltd.(up 1.23 per cent) ended the day as top gainers in the pack.

Deloitte and industry chamber ASSOCHAM. It acknowledged that India's pharmaceutical ecosystem is transforming significantly, supported by comprehensive regulatory and policy reforms to foster innovation and growth. The regulatory framework, which governs drug discovery, development and commercialisation, is being actively enhanced to streamline approval processes, increase transparency and reduce barriers to entry for innovative products.

It now often takes 9-12 months to fill a vacant CEO or CXO position, especially when the search is for seasoned professionals in specialised areas such as renewables, semiconductors, chemicals, hightech manufacturing, automotive and electric vehicles, pharmaceuticals and hardcore product engineering, they said. Usually, a senior executive search used to be closed in 3-4 months in times when the demand-supply mismatch was not so acute as it has been in the last one year. There is an increasing trend among senior professionals to have exploratory chats. Some may also not accept the offer made at the very last minute. It is all a result of a leadership market where demand for talent — especially in some of the newer areas — far out surpasses supply,” said the head of HR at a large industrial company, who did not wish to be named. This is one of the reasons why companies are increasingly building a leadership pipeline nternally, the HR head said. The internal candidate in such cases is given preference over an external executive even if the former is only 60% ready to take charge. But in case of specialised roles, often there is no option but to look for professionals outside.

Carlyle investee companies Sequent Scientific and Viyash Life Sciences announced a merger that will create a platform with leadership in animal pharmaceuticals and expanded capabilities across the larger global pharmaceutical market, including in research and development. ET in its online edition on Thursday afternoon reported first about talks between Sequent Scientific and Viyash Life Sciences for a ₹7,000 crore-₹8,000 crore merger.

Paliperidone extended-release tablets indicated for the treatment of schizophrenia. The approval by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Alembic Pharmaceuticals said in a regulatory filing. The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Invega extended-release tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Pharmaceuticals, Inc, it added. Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for the treatment of schizophrenia and it is also indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilisers and/or antidepressants.

The NSE Nifty index ended the session 37.1 points down at 26178.95, while BSE Sensex fell 264.27 points to 85571.85.

Carlyle Group portfolio companies Sequent Scientific and Viyash Life Sciences are in advanced talks for a potential Rs 7,000-8,000 crore merger, according to people familiar with the matter. Boards of both companies are likely to discuss the possibility in the coming week, according to those cited. There is no certainty a transaction will materialise, they said. Sequent is listed and Viyash isn't. Viyash generated 1.5 times the operating profits of Sequent in FY24, said the people quoted above, adding that the two are exploring the merger due to possible back-end synergies. ET first reported the story online on Thursday.

Produce importer Peter Kopke, Sr. discusses the impact of a looming port strike on The Bottom Line.

Sequent Scientific and Viyash Life Sciences are in talks for a potential merger worth Rs. 7000-8000 crore, according to people familiar with the matter. The former is listed and the latter unlisted. The two companies boards are likely to hold independent meetings to discuss the possibility of a deal in the coming weeks, according to the sources. There is no certainty a transaction will materialize, they said.

Abbott India Ltd.(up 0.79 per cent), Sun Pharmaceutical Industries Ltd.(up 0.73 per cent), Granules India Ltd.(up 0.57 per cent), Dr. Reddy's Laboratories Ltd.(up 0.56 per cent) and J B Chemicals & Pharmaceuticals Ltd.(up 0.48 per cent) were among the top gainers.

National Association of Wholesaler-Distributors CEO Eric Hoplin discusses potential port strikes on Mornings with Maria.

State Bank of India (SBI), ICICI Bank, pharmaceutical major Famy Care, family offices and high networth individuals (HNIs). Over Rs 300 crore of the funds raised to date have already been committed towards five projects of the Rustomjee Group in some of Mumbai's prime locations and the fund is now exercising its green shoe option with a target of a final close shortly. The identified projects for investments include projects in Bandra West’s Pali Hill and Mt Mary Road, Versova Beach in Andheri West, Dhuruvadi in Prabhadevi and one more in Pali Hill. The Versova Beach and one Pali Hill project have already secured the necessary approvals, with construction in progress and active upward sales.

Key export sectors include electronics, pharmaceuticals, and perishables, with companies like DHL predicting a 20% annual growth rate in the industry. «We're bullish,» said Etihad CEO Antonoaldo Neves, highlighting that cargo potential from India. DHL CEO Pablo Ciano also identified significant growth areas in contract logistics and cross-border trade, emphasising that India's finished goods exports are growing at «20% year over year.» The logistics landscape is evolving, with increased investments in warehousing and fulfillment centers tailored to sectors like life sciences and healthcare.

Shares of Glenmark Pharmaceuticals Ltd.(up 4.63 per cent), Mankind Pharma Ltd.(up 4.52 per cent), J B Chemicals & Pharmaceuticals Ltd.(up 2.89 per cent), Gland Pharma Ltd.(up 2.55 per cent) and Laurus Labs Ltd.(up 1.58 per cent) ended the day as top gainers in the pack.

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from a Phase 2a trial of its experimental obesity pill monlunabant that came in below market expectations. Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of monlunabant, an experimental drug it acquired as part of its $1 billion purchase of Canadian biotech company Inversago Pharmaceuticals last year.

Mankind Pharma has approved raising Rs 10,000 crore through the issuance of non-convertible debentures (NCDs) and commercial papers on a private placement basis. The board has also constituted and authorized the fund raising committee to take all necessary actions, including finalisation of the terms of issuance, allotment of NCDs and CPs and other related matters.

Shares of Granules India Ltd.(up 0.6 per cent) and Divi's Laboratories Ltd.(up 0.32 per cent) ended the day as top gainers in the pack.